Cargando…

Genetic heterogeneity in response to adenovirus gene therapy

BACKGROUND: After intravenous delivery of the adenoviral vector into rats or mice, 95–99% of the encoded protein is produced in the hepatocytes. We observed, as have others, that the early expression levels of the vector encoded protein vary, greatly, within a species, from one animal strain to anot...

Descripción completa

Detalles Bibliográficos
Autores principales: Lefesvre, Pierre, Attema, Joline, Lemckert, Angelique, Havenga, Menzo, Bekkum, Dirk van
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC155537/
https://www.ncbi.nlm.nih.gov/pubmed/12697054
http://dx.doi.org/10.1186/1471-2199-4-4
_version_ 1782120755353354240
author Lefesvre, Pierre
Attema, Joline
Lemckert, Angelique
Havenga, Menzo
Bekkum, Dirk van
author_facet Lefesvre, Pierre
Attema, Joline
Lemckert, Angelique
Havenga, Menzo
Bekkum, Dirk van
author_sort Lefesvre, Pierre
collection PubMed
description BACKGROUND: After intravenous delivery of the adenoviral vector into rats or mice, 95–99% of the encoded protein is produced in the hepatocytes. We observed, as have others, that the early expression levels of the vector encoded protein vary, greatly, within a species, from one animal strain to another. This study was initiated to determine the molecular mechanism causing the difference: hepatic transfection, transcription or translation. For this purpose different doses of Ad5 luciferase and Ad5 LacZ were intravenously injected into Brown Norway rats and Wag/Rij rats, two strains that differ by a factor of 10 in encoded protein levels. The proportion of LacZ positive hepatocytes, the adenoviral DNA, specific transgenic RNA and luciferase protein were compared in the two strains. RESULTS: The number of transduced hepatocytes and the amounts of Ad5 DNA in the livers was similar in both strains, whereas the Brown Norway rats produced 8 to 10 times more of both vector encoded proteins and of transgene mRNA than the Wag/Rij rats. CONCLUSIONS: It is concluded that the difference between strains in vector encoded protein expression is due to different transcriptional events. No evidence was obtained to suggest that the differences are related to liver damage influenced by vector toxicity or immune reactions.
format Text
id pubmed-155537
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-1555372003-05-17 Genetic heterogeneity in response to adenovirus gene therapy Lefesvre, Pierre Attema, Joline Lemckert, Angelique Havenga, Menzo Bekkum, Dirk van BMC Mol Biol Research Article BACKGROUND: After intravenous delivery of the adenoviral vector into rats or mice, 95–99% of the encoded protein is produced in the hepatocytes. We observed, as have others, that the early expression levels of the vector encoded protein vary, greatly, within a species, from one animal strain to another. This study was initiated to determine the molecular mechanism causing the difference: hepatic transfection, transcription or translation. For this purpose different doses of Ad5 luciferase and Ad5 LacZ were intravenously injected into Brown Norway rats and Wag/Rij rats, two strains that differ by a factor of 10 in encoded protein levels. The proportion of LacZ positive hepatocytes, the adenoviral DNA, specific transgenic RNA and luciferase protein were compared in the two strains. RESULTS: The number of transduced hepatocytes and the amounts of Ad5 DNA in the livers was similar in both strains, whereas the Brown Norway rats produced 8 to 10 times more of both vector encoded proteins and of transgene mRNA than the Wag/Rij rats. CONCLUSIONS: It is concluded that the difference between strains in vector encoded protein expression is due to different transcriptional events. No evidence was obtained to suggest that the differences are related to liver damage influenced by vector toxicity or immune reactions. BioMed Central 2003-04-05 /pmc/articles/PMC155537/ /pubmed/12697054 http://dx.doi.org/10.1186/1471-2199-4-4 Text en Copyright © 2003 Lefesvre et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.
spellingShingle Research Article
Lefesvre, Pierre
Attema, Joline
Lemckert, Angelique
Havenga, Menzo
Bekkum, Dirk van
Genetic heterogeneity in response to adenovirus gene therapy
title Genetic heterogeneity in response to adenovirus gene therapy
title_full Genetic heterogeneity in response to adenovirus gene therapy
title_fullStr Genetic heterogeneity in response to adenovirus gene therapy
title_full_unstemmed Genetic heterogeneity in response to adenovirus gene therapy
title_short Genetic heterogeneity in response to adenovirus gene therapy
title_sort genetic heterogeneity in response to adenovirus gene therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC155537/
https://www.ncbi.nlm.nih.gov/pubmed/12697054
http://dx.doi.org/10.1186/1471-2199-4-4
work_keys_str_mv AT lefesvrepierre geneticheterogeneityinresponsetoadenovirusgenetherapy
AT attemajoline geneticheterogeneityinresponsetoadenovirusgenetherapy
AT lemckertangelique geneticheterogeneityinresponsetoadenovirusgenetherapy
AT havengamenzo geneticheterogeneityinresponsetoadenovirusgenetherapy
AT bekkumdirkvan geneticheterogeneityinresponsetoadenovirusgenetherapy